Rebecca S Boxer1, Brian D Hoit2, Brian J Schmotzer3, Gregory T Stefano2, Amanda Gomes4, Lavinia Negrea2. 1. Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: rebecca.boxer@ucdenver.edu. 2. Department of Medicine, Case Western Reserve University, Cleveland, Ohio. 3. Center for Clinical Investigation, Case Western Reserve University, Cleveland, Ohio. 4. McLaren Health Care, Bay City, Michigan.
Abstract
BACKGROUND:Vitamin D deficiency is associated with heart failure (HF) events, and in animal models vitamin D down-regulates renin-angiotensin-aldosterone system hormones. METHODS:Patients with New York Heart Association (NYHA) functional class II-IV HF and a 25OH-D level ≤37.5 ng/mL received 50,000IU vitamin D3 weekly (n = 31) or placebo (n = 33) for 6 months. Serum aldosterone, renin, echocardiography, and health status were determined at baseline and 6 months. RESULTS:Mean age of participants was 65.9 ± 10.4 years, 48% were women, 64% were African American, mean ejection fraction was 37.6 ± 13.9%, 36% were in NYHA functional class III, and 64% were in class II. The vitamin D group increased serum 25OH-D (19.1 ± 9.3 to 61.7 ± 20.3 ng/mL) and the placebo group did not (17.8 ± 9.0 to 17.4 ± 9.8 ng/mL). Aldosterone decreased in the vitamin D group (10.0 ± 11.9 to 6.2 ± 11.6 ng/dL) and not in the placebo group (8.9 ± 8.6 to 9.0 ± 12.4 ng/dL; P = .02). There was no difference between groups in renin, echocardiographic measures, or health status from baseline to 6 months. Modeling indicated that variables which predicted change in aldosterone included receiving vitamin D, increasing age, African American race, and lower glomerular filtration rate. CONCLUSIONS:Vitamin D3 repletion decreases aldosterone in patients with HF and low serum vitamin D. Vitamin D may be an important adjunct to standard HF therapy. Further study will assess if vitamin D provides long-term benefit for patients with HF.
RCT Entities:
BACKGROUND:Vitamin D deficiency is associated with heart failure (HF) events, and in animal models vitamin D down-regulates renin-angiotensin-aldosterone system hormones. METHODS:Patients with New York Heart Association (NYHA) functional class II-IV HF and a 25OH-D level ≤37.5 ng/mL received 50,000 IU vitamin D3 weekly (n = 31) or placebo (n = 33) for 6 months. Serum aldosterone, renin, echocardiography, and health status were determined at baseline and 6 months. RESULTS: Mean age of participants was 65.9 ± 10.4 years, 48% were women, 64% were African American, mean ejection fraction was 37.6 ± 13.9%, 36% were in NYHA functional class III, and 64% were in class II. The vitamin D group increased serum 25OH-D (19.1 ± 9.3 to 61.7 ± 20.3 ng/mL) and the placebo group did not (17.8 ± 9.0 to 17.4 ± 9.8 ng/mL). Aldosterone decreased in the vitamin D group (10.0 ± 11.9 to 6.2 ± 11.6 ng/dL) and not in the placebo group (8.9 ± 8.6 to 9.0 ± 12.4 ng/dL; P = .02). There was no difference between groups in renin, echocardiographic measures, or health status from baseline to 6 months. Modeling indicated that variables which predicted change in aldosterone included receiving vitamin D, increasing age, African American race, and lower glomerular filtration rate. CONCLUSIONS:Vitamin D3 repletion decreases aldosterone in patients with HF and low serum vitamin D. Vitamin D may be an important adjunct to standard HF therapy. Further study will assess if vitamin D provides long-term benefit for patients with HF.
Authors: John Spertus; Eric Peterson; Mark W Conard; Paul A Heidenreich; Harlan M Krumholz; Philip Jones; Peter A McCullough; Ileana Pina; Joseph Tooley; William S Weintraub; John S Rumsfeld Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Michel F Rousseau; Olivier Gurné; Daniel Duprez; Walter Van Mieghem; Annie Robert; Sylvie Ahn; Laurence Galanti; Jean Marie Ketelslegers Journal: J Am Coll Cardiol Date: 2002-11-06 Impact factor: 24.094
Authors: Wei Xiang; Juan Kong; Songcang Chen; Li-Ping Cao; Guilin Qiao; Wei Zheng; Wenhua Liu; Xinmin Li; David G Gardner; Yan Chun Li Journal: Am J Physiol Endocrinol Metab Date: 2004-09-14 Impact factor: 4.310
Authors: Ulrich P Jorde; Timothy Vittorio; Stuart D Katz; Paolo C Colombo; Farhana Latif; Thierry H Le Jemtel Journal: Circulation Date: 2002-08-27 Impact factor: 29.690
Authors: Klaus K Witte; Rowena Byrom; John Gierula; Maria F Paton; Haqeel A Jamil; Judith E Lowry; Richard G Gillott; Sally A Barnes; Hemant Chumun; Lorraine C Kearney; John P Greenwood; Sven Plein; Graham R Law; Sue Pavitt; Julian H Barth; Richard M Cubbon; Mark T Kearney Journal: J Am Coll Cardiol Date: 2016-04-04 Impact factor: 24.094
Authors: Armin Zittermann; Jana B Ernst; Sylvana Prokop; Uwe Fuchs; Jens Dreier; Joachim Kuhn; Cornelius Knabbe; Jochen Börgermann; Heiner K Berthold; Stefan Pilz; Ioanna Gouni-Berthold; Jan F Gummert Journal: Int J Endocrinol Date: 2018-07-03 Impact factor: 3.257